New therapeutic options for the metabolic syndrome: What's next?

Trends in Endocrinology and Metabolism

Volumn 16, Issue 6, 2005, Pages 254-260

  Flordellis, Christodoulos S ^a   Ilias, Ioannis ^a   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; 4 [2 [(2 HYDROXY 2 PHENYLETHYL)AMINO]PROPYL]BENZOIC ACID METHYL ESTER HYDROGEN MALEATE; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID METHYL ESTER; AD 9677; ADENOVIRUS VECTOR; ADIPONECTIN; ANTIDIABETIC AGENT; ARH 039242; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETACELLULIN; BIGUANIDE; BVT 3498; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GW 365; GW 409544; HELENALIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTACYSTIN; LEPTIN; LG 101506; LIRAGLUTIDE; LY 377604; LY 465608; METFORMIN; NC 2100; NEUROGENIC DIFFERENTIATION FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; SDZ CP 1975; SIBUTRAMINE; T 1317; TESAGLITAZAR; TETRAHYDROLIPSTATIN; TORCETRAPIB; TRANSCRIPTION FACTOR PDX 1; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; BRAIN REGION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG MECHANISM; DYSLIPIDEMIA; GENE; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORGAN INJURY; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PATHOGENESIS; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; VIRAL GENE THERAPY;

EID: 23044443259     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2005.06.001     Document Type: Article

References (68)

1. U.N. Das Is metabolic syndrome X an inflammatory condition? Exp. Biol. Med. (Maywood) 227 2002 989 997
2. S.M. Grundy Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition Circulation 109 2004 433 438
3. D.O. Smith, and D. LeRoith Insulin resistance syndrome, pre-diabetes, and the prevention of type 2 diabetes mellitus Clin. Cornerstone 6 2004 7 13
4. D. Einhorn American College of Endocrinology position statement on the insulin resistance syndrome Endocr. Pract. 9 2003 237 252
5. Anonymous The rising tide of metabolic syndrome Postgrad. Med. 116 2004 54i 54vii
6. H.E. Lebovitz, and M.A. Banerji Treatment of insulin resistance in diabetes mellitus Eur. J. Pharmacol. 490 2004 135 146
7. A. Sjoholm, and T. Nystrom Endothelial inflammation in insulin resistance Lancet 365 2005 610 612
8. Y. Lee β-Cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-β-cell relationships Proc. Natl. Acad. Sci. U. S. A. 91 1994 10878 10882
9. A. Virkamaki Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle Diabetes 50 2001 2337 2343
10. C.B. Newgard, and J.D. McGarry Metabolic coupling factors in pancreatic-cell signal transduction Annu. Rev. Biochem. 64 1995 689 719
11. S. Mathias Signal transduction of stress via ceramide Biochem. J. 335 1998 465 480
12. M. Shimabukuro Fatty acid-induced β-cell apoptosis: a link between obesity and diabetes Proc. Natl. Acad. Sci. U. S. A. 95 1998 2498 2502
13. K.T. Lin Peroxynitrite-induced apoptosis in HL-69 cells J. Biol. Chem. 270 1995 16487 16490
14. R.H. Unger Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine Biochimie 87 2005 57 64
15. G.A. Francis PPAR agonists in the treatment of atherosclerosis Curr. Opin. Pharmacol. 3 2003 186 191
16. G.D. Barish, and R.M. Evans PPARs and LXRs: atherosclerosis goes nuclear Trends Endocrinol. Metab. 15 2004 158 165
17. J. Berger, and D.E. Moller The mechanisms of action of PPARs Annu. Rev. Med. 53 2002 409 435
18. F. Picard, and J. Auwerx PPARγ and glucose homeostasis Annu. Rev. Nutr. 22 2002 167 197
19. C. Blanquart Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation J. Steroid Biochem. Mol. Biol. 85 2003 267 273
20. A. Peters-Harmel Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes Curr. Med. Res. Opin. 20 2004 215 223
21. A.L. Hevener Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male Wistar rats Diabetes 50 2001 2316 2322
22. C.J. Fielding, and P.E. Fielding Molecular physiology of reverse cholesterol transport J. Lipid Res. 36 1995 211 228
23. K.E. Wellen Interaction of TNF-α- and thiazolidinedione-regulated pathways in obesity Endocrinology 145 2004 2214 2220
24. J.R. Schultz Role of LXRs in control of lipogenesis Genes Dev. 14 2000 2831 2838
25. B.A. Laffitte Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue Proc. Natl. Acad. Sci. U. S. A. 100 2003 5419 5424
26. A. Pawar The role of liver X receptor-α in the fatty acid regulation of hepatic gene expression J. Biol. Chem. 278 2003 40736 40743
27. K.R. Steffensen, and J.A. Gustafsson Putative metabolic effects of the liver X receptor (LXR) Diabetes 53 2004 S36 S42
28. K.N. Hewitt Minireview: hexose 6-phosphate dehydrogenase and redox control of 11β-hydroxysteroid dehydrogenase type 1 activity Endocrinology 146 2005 2539 2543
29. T.P. Combs Induction of adipocyte complement-related protein of 30 kilodaltons by PPAR-γ agonists: a potential mechanism of insulin sensitization Endocrinology 143 2002 998 1007
30. C.A. Baumann CAP defines a second signalling pathway required for insulin-stimulated glucose transport Nature 407 2000 202 207
31. A.W. Norris Muscle-specific PPAR-γ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones J. Clin. Invest. 112 2003 608 618
32. G. Martin Coordinate regulation of the expression of the fatty acid transport protein and Acyl-CoA synthetase genes by PPARα and PPARγ activators J. Biol. Chem. 272 1997 28210 28217
33. Y. Takata Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-δ and peroxisome proliferator-activated receptor-γ Circ. Res. 91 2002 427 433
34. K.A.R. Tobin Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-α Mol. Endocrinol. 14 2000 741 752
35. T. Collins, and M.I. Cybulsky NF-κB: pivotal mediator or innocent bystander in atherogenesis? J. Clin. Invest. 107 2001 255 264
36. S. Obici Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production Nat. Med. 9 2003 756 761
37. J.R.S. Arch β3-Adrenoceptor agonists: potential, pitfalls and progress Eur. J. Pharmacol. 440 2002 99 107
38. L. Cheng Cardiomyocyte-restricted peroxisome proliferator-activated receptor-δ deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy Nat. Med. 10 2004 1245 1250
39. P.M. Stewart Tissue-specific Cushing's syndrome, 11β-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action Eur. J. Endocrinol. 149 2003 163 168
40. M. Faraj Diabetes, lipids, and adipocyte secretagogues Biochem. Cell Biol. 82 2004 170 190
41. C. Hug, and H.F. Lodish The role of the adipocyte hormone adiponectin in cardiovascular disease Curr. Opin. Pharmacol. 5 2005 129 134
42. J.M. Way Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor γ agonists J. Biol. Chem. 276 2001 25651 25653
43. C.P. Busch, and R.A. Hegele Genetic determinants of type 2 diabetes mellitus Clin. Genet. 60 2001 243 254
44. J. Masugi Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-γ2 on thiazolidinedione-induced adipogenesis Biochem. Biophys. Res. Commun. 268 2000 178 182
45. S. Kojima Levels of the adipocyte-derived plasma protein, adiponectin, have a close relationship with atheroma Thromb. Res. 115 2005 483 490
46. E. Kanters Inhibition of NF-κB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice J. Clin. Invest. 112 2003 1176 1185
47. E. Danforth Jr Sibutramine and thermogenesis in humans Int. J. Obes. Relat. Metab. Disord. 23 1999 1007 1008
48. G.A. Bray, and F.L. Greenway Current and potential drugs for treatment of obesity Endocr. Rev. 20 1999 805 875
49. M.H. Moneva, and S. Dagogo-Jack Multiple drug targets in the management of type 2 diabetes Curr. Drug Targets 3 2002 203 221
50. S.M. Setter Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy Clin. Ther. 25 2003 2991 3026
51. H.S. Camp Thiazolidinediones in diabetes: current status and future outlook Curr. Opin. Investig. Drugs 4 2003 406 411
52. D. Duran-Sandoval Pharmacologie des agonistes de PPARα et PPARγ et des activateurs PPARα/γ mixtes en developpement clinique Med. Sci. (Paris) 19 2003 819 825
53. G.J. Etgen A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-α/γ agonist ly465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models Diabetes 51 2002 1083 1087
54. Y. Fukui A new thiazolidinedione, NC-2100, which is a weak PPAR-γ activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice Diabetes 49 2000 759 767
55. M.M. Faul, and T.A. Grese Selective RXR modulators for the treatment of type II diabetes Curr. Opin. Drug Discov. Dev. 5 2002 974 985
56. G. Lyss The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-κB by directly targeting p65 J. Biol. Chem. 273 1998 33508 33516
57. G. Lyss Helenalin, an anti-inflammatory sesquiterpene lactone from arnica, selectively inhibits transcription factor NF-κB Biol. Chem. 378 1997 951 961
58. G. Fenteany Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin Science 268 1995 726 731
59. L.R. Dick Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells J. Biol. Chem. 272 1997 182 188
60. M.B. Grisham Inhibition of NF-κB activation in vitro and in vivo: role of 26S proteasome Methods Enzymol. 300 1999 345 363
61. T. Yotsumoto Effects of carnitine palmitoyltransferase I inhibitors on hepatic hypertrophy Eur. J. Pharmacol. 398 2000 297 302
62. B. Hu, and L.L. Jennings Orally bioavailable β3-adrenergic receptor agonists as potential therapeutic agents for obesity and type-II diabetes Prog. Med. Chem. 41 2003 167 194
63. M.A. Nauck, and J.J. Meier Glucagon-like peptide 1 and its derivatives in the treatment of diabetes Regul. Pept. 128 2005 135 148
64. Y. Qi Adiponectin acts in the brain to decrease body weight Nat. Med. 10 2004 524 529
65. W.A. van der Steeg Role of CETP inhibitors in the treatment of dyslipidemia Curr. Opin. Lipidol. 15 2004 631 636
66. Anonymous Exenatide (Byetta) for type 2 diabetes Med. Lett. Drugs Ther. 47 2005 45 46
67. P.S. Kalra, and S.P. Kalra Obesity and metabolic syndrome: long-term benefits of central leptin gene therapy Drugs Today (Barc) 38 2002 745 757
68. H. Kojima NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice Nat. Med. 9 2003 596 603